Insulet Corporation (PODD) Getting Somewhat Positive Media Coverage, Study Shows
News articles about Insulet Corporation (NASDAQ:PODD) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insulet Corporation earned a news impact score of 0.14 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 45.9660126352604 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Transenterix : Medical Supplies Stocks on Investors’ Radar — Insulet, Glaukos, West Pharmaceutical Services, and TransEnterix (4-traders.com)
- Insulet Corporation (PODD) Director Purchases $168,625.00 in Stock (americanbankingnews.com)
- Insulet Corporation to Present at Upcoming Investor Conference (finance.yahoo.com)
- ETFs with exposure to Insulet Corp. : November 13, 2017 (finance.yahoo.com)
- Insulet Corporation (PODD) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
PODD has been the subject of several research reports. Jefferies Group LLC lifted their price target on Insulet Corporation from $58.00 to $67.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Wedbush reiterated a “buy” rating and set a $65.00 price target (up from $60.00) on shares of Insulet Corporation in a report on Tuesday, October 10th. Zacks Investment Research lowered Insulet Corporation from a “buy” rating to a “hold” rating in a report on Saturday. Canaccord Genuity reiterated a “hold” rating and set a $50.00 price target on shares of Insulet Corporation in a report on Wednesday, September 27th. Finally, Robert W. Baird set a $65.00 price target on Insulet Corporation and gave the company a “buy” rating in a report on Friday, October 13th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Insulet Corporation has an average rating of “Buy” and a consensus target price of $58.87.
Shares of Insulet Corporation (NASDAQ:PODD) traded up $0.44 during mid-day trading on Wednesday, hitting $67.86. The stock had a trading volume of 589,400 shares, compared to its average volume of 499,314. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. Insulet Corporation has a 12 month low of $32.12 and a 12 month high of $72.26.
Insulet Corporation (NASDAQ:PODD) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.06. The company had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. Insulet Corporation had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.05) earnings per share. equities analysts predict that Insulet Corporation will post -0.42 EPS for the current year.
In other news, EVP Charles Alpuche purchased 2,500 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were acquired at an average price of $58.08 per share, with a total value of $145,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/15/insulet-corporation-podd-getting-somewhat-positive-media-coverage-study-shows.html.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.